Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mg adl score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Minimal0–2
  • Mild3–6
  • Moderate7–12
  • Severe13–18
Direct Clinical Answer

The Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale calculator is designed for bedside assessing disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms in clinical practice. The resulting score directly guides.

Clinical Guidelines & Evidence

Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.

Clinical Indication

The Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale is indicated for bedside clinical practice to support Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.

Limitations & Contraindications

Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.

Clinical Pearls & Action Plan

Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Widely used in clinical trials and routine clinical practice for monitoring disease severity and treatment response.

Formula & Variables:

MG-ADL Total Score = Talking + Chewing + Swallowing + Breathing + Brushing teeth/combing hair + Rising from chair + Eyelid droop + Double vision (each item scored 0-3)

Input Parameters

NameTypeRequiredDescription
talkingintegerYesDifficulty with speech due to muscle weakness affecting vocal cords and mouth muscles
chewingintegerYesDifficulty with chewing due to weakness of masticatory muscles
swallowingintegerYesDifficulty with swallowing due to weakness of pharyngeal and esophageal muscles
breathingintegerYesRespiratory muscle weakness affecting breathing function
brushing_teeth_combing_hairintegerYesDifficulty with arm elevation and sustained muscle activity for personal care
rising_from_chairintegerYesDifficulty rising from seated position due to proximal leg muscle weakness
eyelid_droopintegerYesPtosis - drooping of upper eyelids due to weakness of levator palpebrae muscles
double_visionintegerYesDiplopia - double vision due to weakness of extraocular muscles

Score Interpretation & Guidance

RangeStageDescription
0–2MinimalMinimal functional impairment
3–6MildMild functional impairment
7–12ModerateModerate functional impairment
13–18SevereSevere functional impairment
19–24Very SevereVery severe functional impairment

Evidence-Based References (EBM)

  • Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.DOI: 10.1212/wnl.52.7.1487
  • Muppidi S, Wolfe GI, Conaway M, Burns TM; MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31. doi: 10.1002/mus.22140.DOI: 10.1002/mus.22140
  • Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434-40. doi: 10.1212/WNL.0b013e3181dc1b1e.DOI: 10.1212/WNL.0b013e3181dc1b1e

Related calculators